David Lee, Director of the Office of Legislative and Regulatory Modernization at Health Canada, presenting on the topic, 'Conditional approvals to fast track drugs to patients' at World Orphan Drug Congress USA 2012. The World Orphan Drug Congress USA is North America's largest commercially-focused orphan drug event. With key topics including regulation, reimbursement, emerging markets, sustainability, stakeholder commitment and collaboration, and overcoming development challenges, this is the place to be! Watch the video for some key insights on the industry. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the rare disease sector.

John Crowley, Chief Executive Officer & Chairman of Amicus Therapeutics, presenting opening remarks at World Orphan Drug Congress USA 2012. The World Orphan Drug Congress USA is North America's largest commercially-focused orphan drug event. With key topics including regulation, reimbursement, emerging markets, sustainability, stakeholder commitment and collaboration, and overcoming development challenges, this is the place to be! Watch the video for some key insights on the industry. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the rare disease sector.

During this free on-demand webinar, Worldwide Clinical Trial experts discuss emerging trends in clinical trial methodology for orphan disease drug development, innovation drivers in orphan disease research, and ways to overcome challenges through the use of observational trials by: - Providing an impetus for further enhancements in the drug development processes in orphan disease research - Describing both benefits and limitations of program innovation from the perspective of patient and family engagement - Expanding the portfolio of observational research methods which can complement product registration programs - Highlighting techniques that have been considered for data analyses and methods of presentation to assist in informing healthcare decisions

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis - RICH TV LIVE - August 4, 2021 - PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Fabio Chianelli, Chief Executive Officer of PharmaTher, said, “Receiving FDA orphan drug designation is a massive validation for ketamine as a potential treatment for ALS, and it allows us to confidently proceed in evaluating ketamine in a phase 2 clinical study in patients suffering from this life-threatening disease. This designation not only expedites our regulatory, clinical and product development plans, but also validates our belief in the potential of ketamine as a therapeutic solution for neurological disorders.” PharmaTher has an exclusive license agreement with The University of Kansas (KU) for the development and commercialization of the intellectual property of ketamine in the treatment of ALS. The FDA evaluated the research data licensed from KU in the ODD application that ultimately served as the foundation to allow the FDA to grant the designation. The Company is also working with clinicians in finalizing a phase 2 study protocol to evaluate ketamine for ALS in the U.S. Ketamine has the potential to effectively increase the life expectancy of those with ALS at any stage and slow the progressive loss of muscle associated with poor outcomes of the disease. The University of Kansas Medical Center researchers and inventors of the potential use of ketamine to treat ALS, Dr. Richard J. Barohn, M.D., John A. Stanford, Ph.D., and Dr. Matthew Macaluso, D.O., have made the promising discovery that ketamine can be administered as an effective treatment for ALS. In addition, unpublished and patent-pending preclinical research has shown that the administration of ketamine preserves muscle function in advancing ALS and increases life expectancy when given in the early stages of muscle decline. Ketamine works by blocking the action of the ionotropic glutamate receptor, the NMDA receptor. Thus, unlike other inhibitors of NMDA receptor function, such as riluzole, ketamine indirectly dampens NMDA receptor-related glutamate excitotoxicity. Further, ketamine can lower D-serine concentrations intracellularly and also partially activates dopamine receptors. Collectively, these mechanisms of ketamine contribute in part to the drug’s neuroprotective effects, which may extend to the motor neurons targeted in ALS. #pharmather #news #richtvlive JOIN RICH TV LIVE TRADING CLUB HERE - http://www.richpicksdaily.com Subscribe - https://www.youtube.com/c/RICHTVLIVE Visit - http://www.richtvlive.com/ & www.richpicksdaily.com a community for stocks, news, and trending topics. #richtvlive #richpicksdaily #stocks Popular Uploads - https://goo.gl/tbvXGg Most Recent Upload - https://goo.gl/unKXBy YouTube Channel Page - https://goo.gl/yUdG7w Subscribe - http://www.youtube.com/c/RICHTVLIVE Rich TV Live Playlist - https://goo.gl/e116JF RICH TV LIVE TOP 10 STOCKS Playlist - https://www.youtube.com/playlist?list... Disclaimer RICH TV LIVE INC. company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RICH TV LIVE reports company profiles or other investor relations materials and presentations are subject to change. RICH TV LIVE and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. RICH TV LIVE INC. sponsored $2,000 CAD for digital video services. Investing is inherently risky. RICH TV LIVE is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov/Canadian CSA https://www.securities-administrators....

Roberta Szydlo from FDA’s Office of Orphan Products Development and Peter Chen from CDER’s Division of User Fee Management & Budget Formulation answer questions from the audience on FDA’s Orphan Drugs Program and priority review vouchers. Find more information at https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/regulatory-education-industry-redi-webinar-financial-incentives-cder-medical-products-june-10-2019 --_______________________________ FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research. Visit https://www.fda.gov/cdersbia and https://www.fda.gov/cdersbialearn for news and a repository of training activities. Email: CDERSBIA@fda.hhs.gov Phone: (301) 796-6707 I (866) 405-5367 LinkedIn: https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance Twitter: https://twitter.com/FDA_Drug_Info CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionmanagement

Rare diseases affect approximately 25-30 million people in Europe, including millions of children. However, since each disease affects less than one person in every 2,000, the pharmaceutical industry has traditionally been reluctant to invest in research and development connected to such illnesses given the small market. In response, legal developments (such as the US Orphan Drug Act 1983 and the EU Orphan Drug Regulation 2000) were enacted in an effort to incentivise innovation. After several decades of operation, are these legal frameworks working well? This symposium seeks to identify and explore what the most pressing priorities are in orphan drug innovation, and whether and how social science research, particularly legal research, can help meet these needs. Hosted by the University of Cambridge, an international hub for legal and scientific expertise, we hope the event will stimulate discussion between legal, economic, business, medical, and scientific experts at a range of career stages. Confirmed participants include: - Timo Minssen (CeBIL, University of Copenhagen) - Kathy Liddell (Centre for Law, Medicine and Life Sciences, University of Cambridge) - Terkel Andersen (EURORDIS) - Thyra de Jongh (Technopolis) - Jakob Wested (Danish Medicines Agency & CeBIL, University of Copenhagen) - Geraldine O'Dea (Health Products Regulatory Agency, Ireland) - Sarah Rickwood (IQVIA) - Sven Bostyn (CeBIL, University of Copenhagen) The 2021 CeBIL Symposium is organised by the Cambridge Centre for Law, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen. The Symposium is generously supported by the Novo Nordisk Foundation.

Marisa Dolled-Filhart, VP of Strategic Alliances at Rare Genomics Institute, presented at World Orphan Drug Congress USA 2013 on the topic, 'Deploying collaborative and innovative approaches from target to drug discovery.' • How early and faster diagnosis are helping rare diseases patients and studies • Is DNA sequencing the most effective approach to discover orphan drugs? • How is prize competition accelerating rare diseases research? World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.

Andrew Callos, Vice President of Commercial Development, Hematology, Endocrinology, Neuroscience and Rare Diseases at Pfizer, presented at World Orphan Drug Congress USA 2013 on the topic, 'Rising to the challenge: building a rare disease franchise, the Pfizer approach.' • Has Pfizer's focus on orphan drugs increased in the last 12 months? • 10 year market projection for this sector • How Pfizer was able to shift from the blockbuster model to niche rare disease patient reach World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.

Brenda Cooperstone, VP of Medicines Development Group at Pfizer, presented at World Orphan Drug Congress USA 2013 on the topic, 'Pfizer's rare disease portfolio.' World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.

Have you ever wondered how pharmaceutical companies are encouraged to develop therapies for rare diseases? And whether or not this system is working? These topics and more are covered in this educational webinar presentation. Watch the presentation to hear us discuss the importance of the Orphan Drug Act, provide an overview of how a drug is developed, and dispel some of the common myths about the process.

Ping Guo, Vice President of Beijing YuanTang Institute of Gene Science at the Ministry of Health in China, presented at World Orphan Drug Congress USA 2013 on the topic, 'Global collaboration for genomic medicine in the new era in healthcare system in China.' • China's healthcare structure and the creation of the SFDA • What could motivate China to create an Orphan Drug Act • Payer and reimbursement system World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.

Martine Zimmermann, Executive Director Global Regulatory Affairs at Alexion Pharmaceuticals, presented at World Orphan Drug Congress USA 2013 on the topic, 'Where industry stumbles in Europe's orphan drug regulatory process.' World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.

Chris Garabedian, Chief Executive Officer of Sarepta Therapeutics, presented at World Orphan Drug Congress USA 2013 on the topic, 'Leveraging a personalized medicine platform: an approach to treat all patient genetic sub-groups in a rare disease.' • Establishing a foundation of evidence • Standardizing the preclinical and clinical approach • The regulatory environment World Orphan Drug Congress USA is the largest international, commercially-focused event for the advancement of rare disease research and orphan drug development. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the orphan drugs and rare disease.

Click here to watch the full webinar for free: https://xtalks.com/webinars/eu-market-access-2021-whats-in-store-for-orphan-drugs-and-atmps/?utm_campaign=&utm_source=Youtube&utm_medium= 2021 had the potential to be a record year for orphan drugs and advanced therapy medicinal products (ATMPs) in Europe. With the hope of a world in which COVID-19 is a manageable disease comes the promise of ground-breaking new therapies and innovative approaches to digital healthcare. Join this webinar to gain valuable insights into changes to the regulatory landscape expected in the coming year, and advice on how sponsors can optimise their commercialisation strategy for orphan drugs and ATMPs in Europe.

Anne Pariser, Associate Director for Rare Diseases at the CDER, part of the FDA, presenting on the topic, 'The importance of natural history studies in rare diseases' at World Orphan Drug Congress USA 2012. The World Orphan Drug Congress USA is North America's largest commercially-focused orphan drug event. With key topics including regulation, reimbursement, emerging markets, sustainability, stakeholder commitment and collaboration, and overcoming development challenges, this is the place to be! Watch the video for some key insights on the industry. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the rare disease sector.

James Cloyd, Director of the Center for Orphan Drug Research, College of Pharmacy at the University of Minnesota, and Nurjana Bachman of Children's Hospital Boston, presenting on the topic, 'Leveraging innovative orphan drug discoveries with academic centers of excellence' at World Orphan Drug Congress USA 2012. Topics include: 1) Applying open innovation techniques to fast track orphan drug development 2) Identifying and partnering with universities and academics 3) IP issues The World Orphan Drug Congress USA is North America's largest commercially-focused orphan drug event. With key topics including regulation, reimbursement, emerging markets, sustainability, stakeholder commitment and collaboration, and overcoming development challenges, this is the place to be! Watch the video for some key insights on the industry. For more information, go to www.terrapinn.com/orphandrug. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the rare disease sector.

Watch the webinar to learn about CENTOGENE's innovative methods to tackle the challenges of orphan drugs in early stage development, clinical trial enrollment, and market development. Our speakers: Oved Amitay, Chief Business Officer Justin Bingham, Vice President Business Development Dr. Peter Bauer, Chief Genomic Officer

Orphan indications and rare diseases remain a big focus for developers and orphan drugs have become one of the fastest growing and areas of drug development, making up an increasingly large proportion of novel drugs hitting the market. It’s also a highly competitive segment of the market, and we’re starting to see some of the dynamics of the wider pharma market coming into play in the more competitive corners of rare diseases. In this webinar, Melanie Senior, Author of Evaluate’s recently published Orphan Drugs report will examine the key highlights with Jeremy M. Levin, CEO, Ovid Therapeutics and Andreas Hadjivasiliou, Managing Analyst, Evaluate.

For his latest Leadership Talks podcast, futurist Mike Walsh talks to AVEVA's Rashesh Mody and GlaxoSmithKline's Antonio Buendia about how Performance Intelligence is bringing about the factories of the future, driving sustainability and enabling digital transformation. Learn more at: www.aveva.com/performance-intelligence

This is an audio version of the Wikipedia Article: https://en.wikipedia.org/wiki/GlaxoSmithKline 00:02:18 1 History 00:02:27 1.1 Glaxo Wellcome 00:06:28 1.2 SmithKline Beecham 00:08:17 1.3 2000: Glaxo Wellcome and SmithKline Beecham merger 00:09:02 1.4 2001–2010 00:10:53 1.5 2011–present 00:15:05 1.5.1 GlaxoSmithKline Consumer Healthcare spin-off 00:15:16 1.5.1.1 GSK–Novartis consumer healthcare buy-out 00:15:54 1.5.1.2 GSK–Pfizer joint venture 00:16:41 1.5.1.3 Subsequent split 00:17:02 1.6 Venture arms 00:17:52 2 Research areas and products 00:18:03 2.1 Pharmaceuticals 00:19:54 2.2 Malaria vaccine 00:21:35 2.3 Consumer healthcare 00:22:35 2.4 Facilities 00:23:04 3 Recognition, philanthropy and social responsibility 00:23:17 3.1 Scientific recognition 00:25:01 3.2 Philanthropy and social responsibility 00:27:45 4 Controversies 00:27:54 4.1 2012 criminal and civil settlement 00:28:05 4.1.1 Overview 00:30:48 4.1.2 Rosiglitazone (Avandia) 00:34:55 4.1.3 Paroxetine (Paxil/Seroxat) 00:37:25 4.1.4 Bupropion (Wellbutrin) 00:38:04 4.2 Antitrust case over griseofulvin 00:39:42 4.3 Ribena 00:40:59 4.4 SB Pharmco Puerto Rico 00:42:42 4.5 China 00:43:45 4.6 Market manipulation in the UK 00:44:29 4.7 Miscellaneous 00:46:34 5 Acquisition-history diagram 00:46:44 6 See also Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago. Learning by listening is a great way to: - increases imagination and understanding - improves your listening skills - improves your own spoken accent - learn while on the move - reduce eye strain Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone. Listen on Google Assistant through Extra Audio: https://assistant.google.com/services/invoke/uid/0000001a130b3f91 Other Wikipedia audio articles at: https://www.youtube.com/results?search_query=wikipedia+tts Upload your own Wikipedia articles through: https://github.com/nodef/wikipedia-tts Speaking Rate: 0.929969402614826 Voice name: en-US-Wavenet-F "I cannot teach anybody anything, I can only make them think." - Socrates SUMMARY ======= GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company as of 2015, after Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi.Emma Walmsley became CEO on 31 March 2017 and is the first female CEO of the company.The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016 it had a market capitalisation of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange. GSK's drugs and vaccines earned revenue of £21.3 billion in 2013. Its top-selling products that year were Advair, Avodart, Flovent, Augmentin, Lovaza and Lamictal. GSK's consumer products, which earned revenue of £5.2 billion in 2013, include Sensodyne and Aquafresh toothpaste, the malted-milk drink Horlicks, Abreva for cold sores, Breathe Right nasal strips, Nicoderm and Nicorette nicotine replacements, and Night Nurse, a cold remedy. The company developed the first malaria vaccine, RTS,S, which it said in 2014 it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization Model List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine. In 2012 GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a $3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company.

Check for GlaxoSmithKline Q2 2020 earnings transcript - https://news.alphastreet.com/earnings-call-transcripts/

Jade is an Industrial Placement Student at GlaxoSmithKline in Pharmaceutical Microbiology. In this video you will learn about Jade and her education, work experience and placement at GSK. She also provides you with advice on your career. Please contact j.law@stempointeast.org.uk with any questions or queries

In this video I give a stock review on the second largest company listed in the FTSE 100, named GlaxoSmithKline and whether you should buy shares of GSK using a UK investing app. I suggest whether GSK stock is worth buying for UK investors, especially when considering the pandemic and health care stock valuations in the UK. Is it time to buy GSK and should you invest your cash into the uk stock market with GSK stock? TRADING 212 FREE SHARE is no longer available due to suspension, however if you'd like a free share worth up to £200, sign up to FREETRADE using this link: https://magic.freetrade.io/join/ozbourne/b604c5b0 Want to keep up with Ozbourne Foreman behind the scenes, such as stocks I'm interested in. Make sure to follow the twitter account @OzbourneForeman or use this link: https://bit.ly/2Y2qiXw If you're interested in signing up to Freetrade, please contact me and I'll send you a referral link. However this is first come first served and there's only one available a week! #GSKSTOCK #UKINVESTINGGSK #GSKSTOCKANALYSIS Disclaimer: I'm not a financial advisor, if you seek financial advice, please see a licensed professional. Sources: https://www.fiercepharma.com/pharma/gsk-kicks-off-2-year-program-to-spin-off-consumer-health-and-possibly-prescription - GlaxoSmithKline + Pfizer split into two companies. https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-gsk/glaxosmithkline-shares - GlaxoSmithKline stock analysis data https://www.dividenddata.co.uk/dividend-history.py?epic=GSK - GlaxoSmithKline dividend history, dividend yield.

Mr. Ralhan speaks about the significance of employment branding and challenges posed by Gen Y to the Recruitment Industry.

GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest health care fraud settlement in U.S. history. (July 2) Subscribe to the Associated Press: http://bit.ly/APYouTube Download AP Mobile: http://www.ap.org/mobile/ Associated Press on Facebook: http://apne.ws/c7lQTV Associated Press on Twitter: http://apne.ws/bTquhb Associated Press on Google+: http://bit.ly/zuTKBL

Khun Viriya GM of GlaxoSmithKline shared his and LEO executive team experiences in SMART Leadership Adventure based learning @ Rai Jai Yim especially in Rock Climbing and Leadership authentic subconscious painting during APIC Unlock Leadership Potential Forum @ Arnoma Hotel. site : http://www.e-apic.com/

Looking for an exciting opportunity with a fast growing pharmaceutical company? You have come to the right place! As a science-led healthcare company, R&D is at the heart of our business. We're looking for the brightest minds to help us continue to discover and develop new medicines, vaccines and consumer healthcare products for those that need them. Are you up for the challenge? On Wednesday, September 15th, 2021, GSK and HBCU CONNECT will host a virtual recruitment event, where you will have the opportunity to learn more about the company and the full time career opportunities available, and also meet some of the team! GSK is looking for experienced professionals in the following areas: Pharmaceutical Sales Marketing Digital Marketing Sales Strategy Strategic Pricing/Finance Pharmaceutical Sales Training Virtual Event Details: WHO: Black Professionals interested in career opportunities nationwide with GSK. WHAT: A virtual event offering a unique opportunity for experienced Black professionals to learn more about GSK and their opportunities in Pharmaceutical Sales, Marketing, Digital Marketing, Sales Strategy, Strategic Pricing/Finance, and Pharmaceutical Sales Training. WHEN: Wednesday, September 15th, 2021 from 6pm to 7:30pm EST. WHERE: Due to COVID-19, this event will be hosted virtually. Details will be shared with confirmed guests via email. To join future events register here: https://hbcuconnect.com/resumes

Speakers: Nicky Clement of Unilever and Mark Lawrence of GlaxoSmithKline Theme: People Analytics #pafow #peopleanalytics #futureofwork #employeeexperience #workerexperience #DEIB #humanizingwork #workforceplanning #workstrategy #peoplestrategy #CSR #ESG #peopledataforgood Learn more about our digital events and the people data for good movement: https://www.pafow.net/ To ongoing learning, creativity, and compassion for the human experience!

Access earnings conference call transcripts at: https://news.alphastreet.com/earnings-call-transcripts/ Earnings Infographics: https://news.alphastreet.com/infographics/ Earnings Calendar: https://news.alphastreet.com/earnings-calendar/ CEO Interviews: https://news.alphastreet.com/interviews/ Listen on: https://podcasts.apple.com/us/podcast/the-earnings-podcast-from-alphastreet/id1535892241?uo=4 https://anchor.fm/earningspodcast/ https://open.spotify.com/show/67gyUX6kl1lpewQcWDvHJ0 https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy8zODY2ZmUwOC9wb2RjYXN0L3Jzcw== https://radiopublic.com/the-earnings-podcast-from-alphast-Gq2Bpo Follow us on: https://twitter.com/AlphSt_Live https://twitter.com/_AlphaStreet https://www.facebook.com/AlphaStreetinc https://www.linkedin.com/company/alphastreet http://www.google.com/news/s/CAowj7D0Cg https://apple.news/TZOi1Q735Ty-T4dxalibGNw Subscribe this channel to listen to earnings call audios

The Instant JChem (IJC) application is a thick client that has been delivered via a desktop application at GSK. The client uses direct connections to the GSK database infrastructure to provide access to registration, biological data and structure searches. Complex data joins and access from sites remote to the data made the connection and query slow for many users. GSK have worked closely with ChemAxon scientists to develop their Plexus Connect tool, as a performant web interface for this client and we are in the process of delivering this new client across GSK. This presentation will reflect on the setup we are changing from, the status of the rollout of the new product, current issues and future challenges.

The deployment of Instant JChem to a global R&D community has recently been implemented. The role of an expert user community, both in the testing and roll-out phases of the project, will be highlighted. This will include the management of user requirements and expectations at several R&D sites and the subsequent IJC experience for scientists at different locations around the globe.

Whitehall Media's 2nd Enterprise Security and Risk Management conference brought together the enterprise IT security and risk management community under one roof to discuss how best to deploy effective business and technology policies and practices within their organisation.

GlaxoSmithKline is a global science-led healthcare company whose mission is to help people do more, feel better, and live longer. In support of this mission, GSK not only discovers, develops and makes medicines that treat a broad range of the world's most common acute and chronic diseases; but also must optimize this process to make them as quickly and widely accessible as possible. But in practice, innovation and process optimization doesn’t come naturally. Our Scientists will often download and deploy niche open source software to solve key scientific problems, resulting in adoption and abandonment of different software components. Additionally, to support the needs of our R&D organization by embedding analytics within the business, we have several Hadoop clusters with different hardware genotypes each with its own respective entry points. So many entry points can become a nightmare to manage let alone customize based on the needs of the end users. In this session, Ranjith Raghunath, Director, Big Data Solutions, Data Centre of Excellence and Lindsay Edwards, Head, Respiratory Data Sciences Group, will share how GSK is using Docker to deliver ‘edge nodes on demand,’ decoupling a gateway from a specific cluster, allowing users to move from one cluster to another while keeping everything they have intact, and reducing deployment of a production grade software package from 6 months to a few hours.

GlaxoSmithKline (GSK) set out to implement STARLIMS at their pharma and consumer health locations around the world to support their manufacturing processes. Challenges were faced, but in the end, GSK received a world-class system that exceeded the needs of its labs by improving turnaround time for testing and successfully replacing older software, Excel, and paper processes. How did they do it? Collaboration! CSols and the STARLIMS technical team worked closely with GSK's product manager, quality team, business analysts, lab leadership, and IT to develop, design, and deploy STARLIMS to their labs across the globe. Watch this webinar and learn how the client achieved success through: - Implementation & Partnership: Review the needs of the lab and how they were met, as a result of the approach and processes leveraged to facilitate the STARLIMS deployment. - Design: Highlight the global structure of the design and configuration and how it was localized for site/lab execution needs by working closely with the GSK product manager and analysts. - Process Execution: Hear how collaboration with GSK's IT and Quality Group ensured repeatable success in Europe, South America, and Asia.

UoB Virtual Careers Fair 2020 - GlaxoSmithKline - Our Early Talent Opportunities: Applying to Graduate Programmes at GSK Watch this video to find out more about what Graduate Programmes are on offer at GSK and what their recruitment process involves.

Steve Goldman discusses how to have a safe, effective drill for your hospital or healthcare facility. Due to the new CMS Emergency Preparedness Guidelines set to be in full effect by November 2017, many emergency planners are looking at ways to improve their drills. Steve has lots of ideas to reviewing and improving your drills to ensure everyone is safe during an incident.

IPC London Sunday Message by Guest speaker Pastor Thomas Philip Venmany (IPC General Joint Secretary)

Music video for On Va Piétiner ft KOFFI OLOMIDE performed by Bebi philip. https://www.youtube.com/channel/UCcVJuyx_vU96hlCMD4zm_Ig https://instagram.com/bebi.philip.5 https://itunes.apple.com/fr/artist/bebi-philip/id425092975 Copyright (C) 2016 BBP Team Records. --- Powered by http://www.vydia.com http://vevo.ly/P9BrDU

Subscribe to the Disaster Empire Website newsletter and follow my blogs at: www.disasterempire.com Ashley Goosman's LinkedIn Profile: www.linkedin.com/in/ashley-goosman Dr. Steve's Profile - linkedin.com/in/dr-steve-goldman-5668844 Crisis Management and Business Resiliency, Advanced Business Resiliency: web.mit.edu/professional/short-programs/courses/crisis_management.html Consulting: SteveGoldmanAssociates.com (Company) More link's to a sampling of Ashley's works: DRJ Career Spotlight: Career Spotlight – https://drj.com/journal_main/career-spotlight-ashley-goosman/ Business Continuity Institute (BCI): Engaging with others is invaluable for your career: https://www.thebci.org/news/engaging-with-others-is-invaluable-for-your-career-interview-with-ashley-goosman.html Continuity Insights: https://continuityinsights.com/the-end-of-business-continuity-as-we-know-it/ If you are interested in sponsoring an upcoming video, being a guest on the channel, or partnering on future blogs, contact me at info@disasterempire.com #massachusettsinstituteoftechnology #education #certification #crisismanagement #resilience #businessresilience #businesscontinuity

'Ek Bhram Sarvagun Sampanna' actress Tina Philip recently postponed her wedding with fiance Nikhil Sharma due to Coronavirus outbreak and she shares how the feeling was like and what precautions she is taking currently. Watch the video to know more. #TinaPhilip #NikhilSharma #SarvagunSampanna

Scottish Communities Climate Action Network General Assembly 13 September 2020 Our community’s chance to steer our support and decide SCCAN’s priority for activities. We explored: Storytelling, Podcasts, Regional Gatherings, Local Zero Carbon Plans, Governance skills and Fundraising. Our keynote speaker is Davie Philip - a Scottish activist who's been advocating for sustainable community in Ireland for over 20 years. He hosts events and facilitates groups - working on collaborative approaches to help their localities flourish - through Cultivate, the trading name of the Sustainable Ireland Cooperative Society he co-founded in 2000. Davie - based at WeCreate, an ecosystem of innovation in Cloughjordan Ecovillage - has served on the Council of ECOLISE, the European network for community-led initiatives on climate change and sustainability for 4 years. He was elected as an ECOLISE co-president - along with Francesca Whitlock of Global Ecovillage Network (GEN) Europe - in 2019. We heard Davie Philip's Presentation on grassroots empowerment in tackling the Climate and Ecological Emergency. Davie is a Scottish activist who's been advocating for a sustainable community in Ireland for over 20 years. He facilitates groups working on collaborative approaches to help localities flourish - through Cultivate, the trading name of the Sustainable Ireland Cooperative Society he co-founded in 2000. Read the full event's report here: https://bit.ly/sccanga13sept Communities for Future website: https://events.communitiesforfuture.org/ http://www.cultivate.ie/about-cultivate-new/our-people http://www.resilience.cultivate.ie/ Scottish Communities Climate Action Network - a network of community groups and organisations taking action on climate change. Our Purpose: To inspire and promote, connect and support community-led action in Scotland to address the Climate Emergency https://www.scottishcommunitiescan.org.uk/

Taking a pet's temperature and having that information automatically added to their medical record would be a huge efficiency gain. This week, Shawn & Ivan chat with Yale Zhang of Mella Pet Care about innovations in workflow through connected devices. Yale recommends Smart People Should Build Things by Andrew Yang (amzn.to/3eq76Kv). Learn more about Yale at mella.ai. 👉 Mentioned in This Episode: - Launching a New Startup With the Same Team - Connecting Medical Devices to Practice Management Software - Creating Devices for Both Veterinarians and Pet Parents Our website: https://www.veterinaryinnovationpodcast.com/ Subscribe: Apple Podcasts - https://apple.co/2Y9joNR Google Podcasts - http://bit.ly/2X36dMZ Google Play - http://bit.ly/2XxdskI Spotify - https://spoti.fi/2KzSw6x Stitcher - http://bit.ly/2Y4ZK5H

Mark Sullivan, mark.f.sullivan@state.ma.us MA Office of International Trade & Investment (MOITI), https://www.mass.gov/orgs/massachusetts-office-of-international-trade-and-investment .. SelectUSA Summit, 1-4 May 2023, Washington, DC https://www.selectusasummit.us/ -- Feel free to contact us with any questions Bill Kenney, bill@meetroi.com MEET, http://meetroi.com/

Mark Sullivan, Chief Growth Officer & Partner of Stonehaven its down with ACG NY during the 15th Annual Healthcare Conference. The event assembled over 450 senior Middle Market Healthcare payers, providers, systems as well as top private equity, family office and strategic buyers representing billions of dollars ready to invest in the North American Healthcare Sector.

Join us as we talk technology, digital currency, and business with Mark Sullivan - EVP at Salesforce https://www.thepavementgroup.com/

Data is widely accepted as an asset, the drive has begun to get the maximum return from it. Hear Mark Sullivan - Global CFO, IDC talk about Data Monetization with Reema Tendulkar on CNBC TV18's TECH @ work. ---------------------------------------------------------------------------------------- Follow IDC India on LinkedIn https://bit.ly/2H1Da8v & Twitter https://bit.ly/2TdBwHf for more updates.

In the future, the limiting factor will be available space. The Founders of SPLT draw from their personal experiences in creating their transportation platform and talk about the direction of the shared economy and how that will help reduce waste, increase sustainability, and bring about the shared transportation platforms of tomorrow. -- Anya Babbitt is the Founder & CEO. She has started multiple businesses and exited one. Anya is resilient, resourceful and a quick decision maker. Having written her thesis on the Kyoto Protocol, Anya is driven to work with cities, corporations and universities to align integrated services thereby reformatting cities of the future. Under Anya's leadership, SPLT has been recognized for 40+ awards and prizes such as the Hult Prize, Google Demo Day, Clean Energy Trust, and Accelerate Michigan as well as press in Huffington Post, Forbes and TechCrunch. SPLT has expanded to serve organizations in the United States, Latin America, and now Europe. Anya is passionate about social responsibility and environmental impact to create a more livable and breathable world with mobility access for all. Yale Zhang, Co-Founder, comes from a background in transportation and logistics, focusing on the warehousing and distribution of physical goods around the United States. He exited a multimillion dollar healthcare products distribution company. In his capacity as Vice President of Wintao Global, they secured multi-year software development contracts with major transportation companies including Dynamex, Datatrac, Marc Global (now a subsidiary of RedPrairie). This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx

Yale Zhang is the founder of hardware start-up Safe Heart, which develops innovative wellness applications, hardware, and accessories. Their flagship product iOximeter is the first pulse oximeter to work on Android and iOS platforms, and a recent finalist on the Engadget Insert Coin competition. The iOximeter is a vital signs monitoring tool for smart phones. It is powered through the phone audio jack. Current features of the app include measurements of the oxygen saturation and heart rate, recording, and alarm functionality. Presentation will go over the conception, research, development, and commercialization of the iOximeter product. Future functionality road map will be revealed. A Q&A session will be held afterwards. The presentation will conclude with a live demo and a device giveaway.

WCX TV sits down with Yale Zhang, Co-Founder of SPLT, to learn about the work that SPLT is doing regarding shared mobility.

By: Jake Voorhees https://www.youtube.com/jakevoorhees Anya Babbitt is the Founder and CEO of Splitting Fares, Inc. (“SPLT”), an enterprise ridesharing platform changing the way people commute together. Ms. Babbitt is a marketing and brand strategist dedicated to fresh insights, authentic messaging and measurable results in sustainability. An experienced entrepreneur, Anya has founded and grown three successful companies and exited one. Anya Babbitt is not your typical entrepreneur. Number one, she is a women in a tech start-up, number two, she is the CEO and number three she is working in an area (transportation) that is dominated by men. Anya, however, is not concerned about the gender inequality or the odds of success–she is laser focused on changing the way people meet and move in urban environments. As a German immigrant, her great grandfather achieved enough success in the United States that he was able to send his five sons to Princeton Prep School and consequently to Princeton University. As a result, Anya believes that the United States provides the best opportunities for innovation and entrepreneurship. She understands and appreciates the supportive environment that allows and encourages her to build and scale her world-changing venture. Anya hopes to inspire other women to pursue entrepreneurship and contribute to creating jobs and socially innovative ventures. Anya has guided SPLT from a small startup in NYC to being chosen for Techstars Mobility 2015 driven by Detroit. Her professional experience spans over 15 years working in the advertising, corporate communications, marketing, product design and sales sector primarily in Boston and New York City, including several years engaged in corporate brand development for multiple brands in domestic and worldwide locations. As a marketing entrepreneur, Anya has successfully provided marketing strategies to such notable institutions and luxury brands as WilmerHale (formerly Hale & Dorr), Trilogy Capital Partners, the Winter Equestrian Festival (WEF), Vicomte A., Hermes, Cartier, Bombardier, Fraser Yachts, L’Oreal, Maybach, the Vicente Fox Center of Studies, Library and Museum, Citizens Energy Corporation and the international and domestic Polo Clubs Association. She has led large teams of individuals working under tight deadlines and with large committed budgets. Her ability to plan ahead and execute under pressure allowed her to excel within the closely tied luxury goods market creating clients out of partnership opportunities. Throughout her career she has been engaged in testing the connection between purpose driven leadership and competitive bottom line performance. As a result, her teams have consistently outperformed peers in both growth and profitability. Since 2014, she has devoted her full attention to the emerging field of social and environmental sustainability, launching SPLT. Yale Zhang is a co-founder of Splitting Fares, Inc. Prior to entering the world of entrepreneurship, Yale’s background was in transportation and logistics, focusing on the warehousing and distribution of physical goods around the United States. In his capacity as Vice President of Wintao Global, they secured multi-year software development contracts with major transportation companies including Dynamex, Datatrac, Marc Global (now a subsidiary of RedPrairie). The insight into these transportation entities allowed Yale to leave and in 2007 start Clinical Guard, his first product distribution company, in medical supplies. The company has grown from an initial annual revenue of $400K to now $3M. Later, he started a medical device innovations company, Safe Heart USA, Inc, focused on creating vital signs monitoring hardware that works in coordination with smartphones running Android and iOS. As the CEO of Safe Heart, Yale has overseen the successful commercialization of research from Oxford University, Emory University, the successful raising of grants from the Atlantic Pediatric Device Consortium, and finally, in raising capital to initially fund a newly emerging business venture. Although Yale has achieved a certain level of success with his involvement in medical devices, his primary passion has always been transportation systems, specifically autonomous vehicles. Yale believes that ongoing technology research by many private and public companies will lead to car ownership reduction as vehicles become autonomous. When that happens, extraordinary opportunities arise for people to share vehicles. He joins SPLT with the intent to help change the behavior of people so that they are comfortable with sharing rides with other people so that everyone will be ready when the autonomous vehicle economy arrives.

PTSD and Pain - A presentation by Dr. Mark Sullivan at the Oregon Pain Guidance conference: 4th Annual Thoughtful Approach to Chronic Pain: New Horizons, What Clearly Works